Iohexol (marketed as OMNIPAQUE™ by GE Healthcare) is the most widely-used injectable diagnostic contrast agent for imaging procedures but has a reported incidence of contrast medium-induced nephropathy, and therefore a significant opportunity exists for a safer alternative formulation. CE-iohexol is expected to potentially establish a new safety standard that enables a future partner to gain meaningful market share.